Amgen Inc. revolutionary blood cancer drug Kyprolis has been fully approved by the U.S. Food and Drug Administration (FDA) as a treatment for patients with multiple myeloma.
The US Food and Drug Administration (FDA) has given their sign of approval on Tuesday, Oct. 27, to Amgen's Imlygic (talimogene laherparepvec), a cancer immunotherapy against the dreaded melanoma lesions found in the skin and lymph nodes.
